Abstract
Des-γ-carboxy prothrombin (DCP) is an aberrant prothrombin produced by hepatocellular carcinoma (HCC) cells. Serum and tissue DCP expressions are thought to reflect the biological malignant potential of HCC. However, the role of DCP in the development of angiogenesis is not well understood. Herein, we report the effects of DCP on growth and migration of human vascular endothelial cells. DCP significantly stimulated the proliferation of HUVEC (ECV304) cells in a dose and time dependent manner, as measured by the MTT assay. A continuous rapid migration of ECV304 cells was observed in the presence of DCP measured by the scratch wound assay. The continuous rapid invasive activity, measured by transwell chamber assay also showed that DCP increased endothelial cells migration through the reconstituted extracellular matrix (Matrigel). Further, the tube formation of vascular endothelial cells on 3-D Matrigel showed an increased number of branch points of ECV304 cells induced by DCP in a dose dependent manner. The levels of vascular endothelial cell growth-related angiogenic factors and matrix metalloproteinase were also examined. DCP significantly stimulated the expression levels of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and matrix metalloproteinase (MMP)-2 (latent and active). Together, these data suggest that DCP is a novel type of vascular endothelial growth factor that possesses potent mitogenic and migrative activities in angiogenesis of HCC.
Similar content being viewed by others
Abbreviations
- HCC:
-
Hepatocellular carcinoma
- DCP:
-
Des-γ-carboxy prothrombin
- HUVEC:
-
Human umbilical vein vascular endothelial cell line
- MTT:
-
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide
- PBS:
-
Phosphate buffered saline
- EDTA:
-
Ethylenediamine tetraacetic acid
- HEPES:
-
Hydroethyl piperazine-ethane sulfonic acid
- ELISA:
-
Enzyme-link immunosorbent assay
- EGFR:
-
Epidermal growth factor receptor
- VEGF:
-
Vascular endothelial growth factor
- MMPs:
-
Matrix metalloproteinase
- ECM:
-
Extracellular matrix
- HGF:
-
Hepatocyte growth factor
- KDR:
-
Kinase insert domain receptor
- MAPK:
-
Mitogen-activated protein kinase
- TGF-β:
-
Transforming growth factor-β
References
Liebman HA (1989) Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 49(23):6493–6497
Kim do Y, Paik YH, Ahn SH et al (2007) PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 72(Suppl 1):52–57. doi:10.1159/000111707
Yuen MF, Lai CL (2005) Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 19(1):91–99. doi:10.1016/j.bpg.2004.10.003
Naraki T, Kohno N, Saito H et al (2002) γ-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochim Biophys Acta 1586(3):287–298. doi:10.1016/S0925-4439(01)00107-7
Suzuki M, Shiraha H, Fujikawa T et al (2005) Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 280(8):6409–6415. doi:10.1074/jbc.M406714200
Gao FJ, Cui SX, Chen MH et al (2008) Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci 83(23–24):815–820. doi:10.1016/j.lfs.2008.10.003
Pang RW, Joh JW, Johnson PJ et al (2008) Biology of hepatocellular carcinoma. Ann Surg Oncol 15(4):962–971. doi:10.1245/s10434-007-9730-z
Shirabe K, Itoh S, Yoshizumi T et al (2007) The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 95(3):235–240. doi:10.1002/jso.20655
Kitai S, Kudo M, Minami Y et al (2008) A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology 51(Suppl 1):86–94. doi:10.1159/000122599
Fujikawa T, Shiraha H, Ueda N et al (2007) Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 282(12):8741–8748. doi:10.1074/jbc.M609358200
Liu J, Li X, Cheng YN et al (2007) Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil. Eur J Pharmacol 574(1):1–7. doi:10.1016/j.ejphar.2007.06.064
Dua P, Gude RP (2008) Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. Eur J Cancer 44(11):1587–1595. doi:10.1016/j.ejca.2008.04.009
Subarsky P, Hill RP (2008) Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells. Clin Exp Metastasis 25(3):253–264. doi:10.1007/s10585-007-9139-x
Yue PY, Wong DY, Wu PK et al (2006) The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 72(4):437–445. doi:10.1016/j.bcp.2006.04.034
Park K, Kim YS, Lee GY et al (2007) Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res 24(1):176–185. doi:10.1007/s11095-006-9139-6
Okutucu B, Dincer A, Habib O et al (2007) Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 70(5):709–711. doi:10.1016/j.jbbm.2007.05.009
Li Z, Zhou Z, Donahue HJ (2008) Alterations in Cx43 and OB-cadherin affect breast cancer cell metastatic potential. Clin Exp Metastasis 25(3):265–272. doi:10.1007/s10585-007-9140-4
Uehara S, Gotoh K, Handa H et al (2005) Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20(10):1545–1552. doi:10.1111/j.1440-1746.2005.03899.x
Sugino T, Yamaguchi T, Hoshi N et al (2008) Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis. Clin Exp Metastasis 25(7):835–841. doi:10.1007/s10585-008-9199-6
Mojzis J, Varinska L, Mojzisova G et al (2008) Antiangiogenic effects of flavonoids and chalcones. Pharmacol Res 57(4):259–265. doi:10.1016/j.phrs.2008.02.005
Klagsbrun M, Moses MA (1999) Molecular angiogenesis. Chem Biol 6(8):R217–R224. doi:10.1016/S1074-5521(99)80081-7
Kemp LE, Mulloy B, Cherardi E (2006) Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. Biochem Soc Trans 34(Pt 3):414–417. doi:10.1042/BST0340414
Moon WS, Park HS, Yu KH et al (2006) Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol 37(10):1324–1332. doi:10.1016/j.humpath.2006.04.022
Black PC, Dinney CP (2007) Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26(3–4):623–634. doi:10.1007/s10555-007-9084-9
Zhu AX, Raymond E (2009) Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Thera 9(1):143–150. doi:10.1586/14737140.9.1.143
Desiderio MA (2007) Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci 64(11):1341–1354. doi:10.1007/s00018-007-7050-x
El-Obeid A, Hesselager G, Westermark B et al (2002) TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor. Biochem Biophys Res Commun 290(1):349–358. doi:10.1006/bbrc.2001.6210
Bellmunt J, Hussain M, Dinney CP (2003) Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46:S85–S104. doi:10.1016/S1040-8428(03)00067-2
Petit AM, Rak J, Huang MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151(6):1523–1530
Okano J, Matsumoto K, Nagahara T et al (2006) Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. J Gastroenterol 41(2):166–176. doi:10.1007/s00535-005-1736-3
Matsuo M, Sakurai H, Koizumi K et al (2007) Curcumin inhibits the formation of capillary-like tubes by rat lymphatic endothelial cells. Cancer Lett 251:288–295. doi:10.1016/j.canlet.2006.11.027
Allen DL, TeiteIbaum DH, Kurachi K (2003) Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol Cell Physiol 284(4):C805–C815. doi:10.1152/ajpcell.00215.2002
Kargozaran H, Yuan SY, Breslin JW et al (2007) A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier. Clin Exp Metastasis 24(7):495–502. doi:10.1007/s10585-007-9086-6
Lai K, Conwav RM, Crouch R et al (2008) Expression and distribution of MMPs and TIMPs in human uveal melanoma. Exp Eye Res 86(6):936–941. doi:10.1016/j.exer.2008.03.010
Werner JA, Rathcke IO, Mandic R (2002) The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis 19(4):275–282. doi:10.1023/A:1015531319087
Acknowledgments
This project was supported by the Natural Science Foundation of China, Shandong Provincial Foundation for Natural Science (Y2006C87) and Shandong University Student’s Innovation Program. This work was also supported in part by Grant-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (20015009). We thank Dr M. D. Lloyd (University of Bath, U. K.) for critically reading this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
S. Cui and X.-J. Qu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Wang, SB., Cheng, YN., Cui, SX. et al. Des-γ-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis 26, 469–477 (2009). https://doi.org/10.1007/s10585-009-9246-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-009-9246-y